Exacerbations, treatment patterns, utilization, and costs before and after initiating of benralizumab for the treatment of severe eosinophilic asthma

CONCLUSIONS: Treatment with benralizumab resulted in fewer exacerbations, reduced utilization, and improved ACT scores. This study demonstrates that benralizumab is an effective treatment option for patients with severe eosinophilic asthma.PMID:38054593 | DOI:10.1080/02770903.2023.2289169

Source: Journal of Asthma - December 6, 2023 Category: Respiratory Medicine Authors: Joseph L Smith Yen Chung John Barron Theodore Barlows Bal Nepal Donna Carstens Source Type: research